An evidence-based approach to recurrent pregnancy loss by Van Niekerk, Elzaan C. et al.
REVIEW
SAJOG • September 2013, Vol. 19, No. 3   61
An evidence-based approach to recurrent pregnancy loss
E C van Niekerk, MB ChB, Dip Obst (SA); I Siebert, MB ChB, MMed (O&G), FCOG, PhD;  
T F Kruger, MB ChB, MParmMed, MMed (O&G), FCOG (SA), MD, FRCOG
Reproductive Biology Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Parow, Cape Town, South Africa
Corresponding author: T F Kruger (tfk@sun.ac.za)
Recurrent pregnancy loss (RPL) can be defined as more than two to three consecutive miscarriages before 24 weeks’ gestation. A 
literature review was done to provide an evidence-based approach to RPL, identifying the risk factors and causes and also looking at the 
various special investigations that form part of the work-up and trying to assess which have been proven to be effective or of negative 
impact, and which of the management options lead to a better outcome. We concluded that the following special investigations should 
be part of the work-up for all patients with RPL: (i) genetic counselling and karyotyping of the abortus; (ii) anticardiolipin antibodies 
and lupus anticoagulant testing must be done on two occasions, 6 - 8 weeks apart; (iii) all patients qualify for a pelvic ultrasound scan 
and hysteroscopy; (iv) syphilis testing must be done routinely; and (v) testing of thyroid function and glucose monitoring/glycosylated 
haemoglobin (HbA1c) measurement must be done in all patients with a history of thyroid disease or diabetes mellitus, or clinical 
manifestations thereof. In approximately 50% of couples the cause of RPL remains unexplained, even after evaluation.
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Recurrent pregnancy loss (RPL), a traumatic experience 
for the patient, is also one of the most difficult areas in 
reproductive medicine. Little consensus exists regarding 
which investigations should be done to identify the 
cause and which treatments are effective, and very 
few are evidence-based. This paper aims to provide the reader with 
a simplified approach in identifying the cause of RPL, to assist with 
everyday management in hospital clinics as well as private practice.
Definition 
According to the Royal College of Obstetricians and Gynaecologists 
(RCOG) Green-top Guideline No. 17, a miscarriage can be defined 
as the spontaneous loss of a pregnancy before the fetus has reached 
viability at 24 weeks.[1] This includes all pregnancy losses from the 
time of conception until 23 completed weeks of gestation. RPL is 
defined as three or more consecutive miscarriages. The World Health 
Organization recommends that in developing countries, where 
gestation is often uncertain, a birth weight of 500 g should be used 
to define viability. The American Society for Reproductive Medicine 
defines RPL as two or more failed pregnancies, which have been 
documented by either ultrasound or histopathological examination. [2] 
They suggest that some investigation must be done after each 
miscarriage, with a thorough evaluation after three or more losses.
Incidence
RPL (as per the classic definition of three or more consecutive 
pregnancy losses) affects 0.4 - 1% of couples.[3] This is approximately 
twice the incidence that would have been expected by chance alone, 
and indicates that an abnormality is likely to be present. The risk 
of miscarriage is also higher the earlier the gestation, the majority 
occurring in the first trimester (Table 1).[4]
Epidemiology
Maternal age
The prevalence of miscarriage increases with advancing maternal 
age (Table 2).[5] The increase in the risk of miscarriage in this group 
is due to an increase in chromosomally abnormal conceptuses, 
probably as a result of poor oocyte quality, and a decline in uterine 
and ovarian function. Advanced paternal age is also a risk factor for 
miscarriage. The risk of miscarriage is highest in couples where the 
woman is older than 35 years and the man older than 40 years.[6]
Reproductive history
A woman’s obstetric history predicts her future risk of miscarriage. 
Both retrospective and prospective studies have shown that the risk 
of another miscarriage increases after each subsequent pregnancy 
loss (Table 3).[7] RPL typically occurs at a similar gestational age in 
consecutive pregnancies.
Risk factors for recurrent pregnancy loss
Genetic factors
Embryonic chromosomal abnormalities (structural and numerical) 
may account for 30 - 57% of miscarriages.[1] Research has shown 
that the risk of aneuploidy increases as the number of previous 
miscarriages increases. Parental chromosomal rearrangements are the 
cause of RPL in 3 - 5% of couples. The most common abnormalities 
are balanced reciprocal or Robertsonian translocations.
Anatomical disorders
Congenital uterine anomalies
Congenital uterine malformations are caused by disturbances 
in Müllerian duct development, fusion, canalisation, and septal 
re absorption.[8] Congenital uterine anomalies most commonly lead to 
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second-trimester miscarriages, and in patients with RPL the contribution 
of congenital uterine anomalies is unclear. The septate uterus is the most 
common uterine abnormality associated with RPL and is associated with 
the poorest reproductive outcome, with a miscarriage rate of more than 
60%. The longer the septum, the poorer the prognosis.[9]
Leiomyoma
The most important factor where fibroids and fertility are concerned 
is the location and not the size of the fibroid. Those that distort the 
uterine cavity, such as submucosal fibroids and intramural fibroids 
with an intracavitary component, have been shown to play a role in 
infertility and are associated with an increased risk of miscarriage. A 
study by Benecke et al.[10] concluded that intramural fibroids cause 
a lower implantation rate per cycle. A meta-analysis by Sunkara et 
al.[11] showed a statistically significant reduction in pregnancy rates 
following in vitro fertilisation (IVF) treatment, even in women with 
non-cavity-distorting intramural fibroids.
Intra-uterine adhesions
Asherman’s syndrome results from vigorous curettage of the 
endometrium, the intra-uterine trauma causing adhesions.[12] This 
may lead to miscarriage because there is insufficient endometrium 
to support fetoplacental growth, but no prospective evidence is 
available to confirm the causal relationship. Genital tuberculosis is a 
cause of intra-uterine adhesions in the developing world.
Cervical incompetence (insufficiency or dysfunction)
Cervical incompetence leads to recurrent mid-trimester mis carriages.
Thrombophilic factors
It has been hypothesised that thrombophilic disorders cause thrombosis of 
the utero-placental vasculature (spiral arteries and intervillous space) due 
to an increased haemostatic response.[13] The subsequent impaired placental 
perfusion may lead to recurrent pregnancy loss, fetal death, pre-eclampsia, 
intra-uterine growth retardation and abruptio placentae.
Inherited thrombophilia is a genetic condition in which there is 
an increased risk of venous thrombosis. The various types are:
• factor V Leiden (FVL) mutation
• prothrombin G20210A gene mutation (PGM)
• protein S deficiency
• protein C deficiency
• antithrombin deficiency.
Of cases of inherited thrombophilia, 50 - 60% are due to FVL 
mutation and PGM. The literature on the association between 
maternal inherited thrombophilia and RPL is mostly contradictory.
Antiphospholipid syndrome
According to the RCOG, antiphospholipid syndrome is the 
most important treatable cause of RPL.[1] It is the only auto-
immune condition in which pregnancy loss is part of the 
diagnostic criteria. Antiphospholipid antibodies (APAs), lupus 
anticoagulant, anticardiolipin antibodies (ACAs) and anti-B2 
glycoprotein-I anti bodies are directed against phospholipid-
binding plasma proteins. Adverse pregnancy outcomes include:
• three or more consecutive unexplained miscarriages before 10 
weeks’ gestation
• one or more deaths of morphologically normal fetuses after the 
10th week of gestation
• one or more preterm births before 34 weeks’ gestation due to 
severe pre-eclampsia, eclampsia or placental insufficiency.
Of patients with RPL, 5 - 15% may have APAs, and the fetal loss rate 
in untreated future pregnancies may be as high as 90%.[14]
Immunological factors
The hypothesis that some cases of RPL may be due to failure of 
maternal allo-immune recognition of the pregnancy has never been 
proven. There is also no evidence to support the hypothesis that 
HLA incompatibility between couples may lead to RPL. Testing of 
these should not be offered to couples.
Uterine natural killer (NK) cells
Some patients with RPL may lack essential components of the 
networks that provide immunological protection to embryos. [1] 
Uterine NK cells appear to regulate placental and trophoblast 
growth and local immunomodulation, and control trophoblast 
invasion. The relationship between uterine NK cell numbers 
and future pregnancy outcome in patients with RPL is still being 
investigated.
Granulocyte-macrophage colony-stimulating factor (G-CSF)
G-CSF is a cytokine with an important regulatory role in 
embryo implantation and subsequent development. G-CSF 
deficiency in pregnancy adversely impacts on fetal and 
placental development.[15] Recent studies have shown that 
the best-quality oocytes come from follicles with the highest 
level of G-CSF. Research has been done to investigate the 
effectiveness of administering G-CSF in preventing embryo 
death in women with RPL. Most of the data show that G-CSF 
may be effective in the treatment of unexplained RPL. However, 
Table 1. Risk of miscarriage at specific gestational ages
Gestation Risk of miscarriage (%)
Before 6 weeks 22 - 57
6 - 10 weeks 15
After 10 weeks 2 - 3
Table 2. Miscarriage rate according to maternal age
Maternal age at conception (years) Miscarriage rate (%)
20 - 24 9
25 - 29 11
30 - 34 15
35 - 39 25
40 - 44 51
>45 75
Table 3. Risk of miscarriage according to obstetric history
Consecutive pregnancies Risk of miscarriage (%)
First pregnancy 5 - 13
After 1 miscarriage 14 - 21
After 2 miscarriages 24 - 29
After 3 miscarriages 31 - 45
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further studies are needed to confirm the effectiveness of this 
treatment.
Endocrine factors
Diabetes mellitus
Several studies have linked high glycosylated haemoglobin 
(HbA1C) values (>8%) early in pregnancy to an increase in 
early pregnancy loss and congenital malformations. There is 
no increased risk of miscarriage in women with well-controlled 
diabetes mellitus.[16]
Polycystic ovarian syndrome (PCOS)
Recent studies have shown that reproductive outcome did 
not differ between patients diagnosed with PCOS and healthy 
controls. The two groups had similar live birth and miscarriage 
rates.[17]
Thyroid antibodies and disease
There are many conflicting reports, and evidence is still lacking 
with regard to the role of thyroid disease in RPL. Some review 
articles conclude that increased serum thyroid antibodies (thyroid 
peroxidase or thyroglobulin) appear to be related to recurrent 
spontaneous miscarriages, even in euthyroid patients,[18] but the 
mechanism is still unclear. Hyperthyroidism (Graves’ disease) 
is associated with spontaneous miscarriage, premature labour, 
low birth weight and perinatal mortality.[19] Hypothyroidism is 
associated with infertility and first-trimester miscarriages, as well 
as perinatal morbidity and mortality.[20]
Luteal phase defect and progesterone deficiency
A functional corpus luteum is essential for successful implantation 
and maintenance of early pregnancy, primarily through 
progesterone production.[21] A luteal phase defect (defect in corpus 
luteum function) with insufficient progesterone production 
results in endometrial development unsuitable for embryonic 
implantation and is associated with RPL. The existence of 
luteal phase defect is controversial, as is whether it is related 
to RPL, mainly because of inconsistencies in its diagnosis and 
management. No evidence could be found in the literature 
regarding a possible association of anti-Müllerian hormone 
deficiency and RPL.
Environmental factors
There is no high-quality evidence that shows any relationship 
between RPL and occupational factors, stress, low-level exposure 
to environmental chemicals, cigarette smoking or caffeine use.[22] 
Moderate to heavy alcohol consumption may increase the risk of 
sporadic miscarriage. Exercise does not appear to increase the rate of 
sporadic or RPL. Recent retrospective studies have shown evidence 
that obesity is a risk factor for infertility, sporadic and RPL and late 
pregnancy complications.
Infection
No infectious agent has been proven to cause RPL. Pregnancies 
complicated by untreated syphilis may lead to RPL if it remains 
untreated in the subsequent pregnancy. The typical history is of 
recurrent mid-trimester miscarriages with macerated fetuses. 
Genital tuberculosis may cause implantation failure or early 
embryonic rejection, leading to RPL and ectopic pregnancy.
Candidates for investigation
It is generally accepted that women without any co-morbid medical 
conditions should not undergo extensive investigations after a 
single miscarriage, and most experts only start with evaluation and 
treatment of RPL after either two or three consecutive miscarriages. 
However, in approximately 50% of these couples the cause of 
RPL remains unexplained. Women with unexplained RPL (>3 
miscarriages) still have an excellent prognosis for future pregnancy 
outcome, with a live birth rate of over 50%.
History and physical examination
The evaluation of any couple with RPL should include a complete 
history, including their ages and an obstetric, gynaecological, 
medical, surgical, genetic, social and family history, as well 
as a physical examination. A detailed history of the previous 
miscarriages is essential, including the gestational age. With 
second-trimester miscarriages, any information that could assist in 
confirming or excluding cervical incompetence should be reviewed 
and the medical notes on the previous miscarriages, whether the 
fetus was macerated or not and whether any uterine abnormalities 
were seen with evacuation, should be noted. Results from previous 
laboratory, pathology and imaging studies must also be obtained.
Investigation of recurrent pregnancy loss
Karyotyping
Karyotyping of products of conception
Cytogenic analysis should be performed on the products of 
conception in all patients with RPL. An abnormal karyotype usually 
indicates a better prognosis for the next pregnancy.[1] Structural 
chromosomal rearrangements in the fetus may be inherited or 
sporadic, and are an indication for parental karyotyping. The role 
of pre-implantational genetic diagnosis (PGD) with IVF has been 
reviewed, and it has been found not to be cost-effective in the 
management of RPL.[23] In patients with RPL the spontaneous birth 
rate is still 50%; with PGD the miscarriage rate may be decreased, but 
only 33% of women become pregnant after each PGD/ IVF cycle.
Parental peripheral blood karyotyping
Selective parental karyotyping is appropriate in cases where 
chromosomal abnormalities were identified in products of 
conception.[1] It must be noted that these investigations are 
expensive and have limited prognostic value and a low yield for 
abnormality, and it is not cost-effective routinely to do karyotyping 
of all couples with RPL. The purpose is to detect balanced 
reciprocal or Robertsonian translocations, or mosaicism that could 
be inherited unbalanced by the fetus. However, chromosomal 
abnormalities detected in parental peripheral blood samples are an 
indirect and limited indicator of fetal karyotype.
Uterine assessment
According to the RCOG, all women with recurrent first-trimester 
miscarriages or with one or more second-trimester miscarriages 
should have a pelvic ultrasound scan to assess the uterine anatomy.[1] 
Thereafter, if uterine anomalies are suspected, further investigations 
can be done to confirm the diagnosis, using hysteroscopy, 
laparoscopy or three-dimensional pelvic ultrasound. Other 
diagnostic modalities are sonohysterography, hysterosalpingography 
and magnetic resonance imaging (MRI). MRI is seldom indicated 
because it is rarely cost-effective.
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Hysteroscopy is seen as the gold standard for the diagnosis of intra-
uterine anomalies, and most abnormalities can also be treated during 
the procedure.[24] Sonohysterography provides information on the 
internal contour of the uterus, as well as the outer surface and uterine 
wall. In comparative studies it was found to be more accurate and to 
provide more information than hysterosalpingography.[25]
Inherited thrombophilias
Testing for inherited thrombophilia in women with a history of 
unexplained RPL is controversial. There are no high-quality, placebo-
controlled, randomised clinical trials to establish the efficacy of 
anticoagulation therapy in preventing RPL. There is also limited 
evidence to help guide the screening process for these conditions.
According to American College of Obstetricians and Gyne cologists 
Practice Bulletin No. 124, inherited thrombophilia testing is not 
recommended for women who have had RPL or placental abruption, 
since it is unclear whether anticoagulation reduces recurrence (level 
B recommendation).[13] Screening with fasting homocysteine levels 
or methylenetetrahydrofolate reductase mutation analyses is not 
recommended (level B recommendation). Screening should be done 
for FVL and PGM, as well as antithrombin, protein C and protein S 
deficiency (level C recommendation). Screening is controversial and 
only useful if the results will affect management decisions, and not 
where treatment is indicated for other risk factors.
The RCOG recommends that women with recurrent second-
trimester miscarriages should be screened for inherited 
thrombophilia. This includes testing for FVL, PGM and protein 
S deficiency (grade D recommendation).[1] This was based on 
a meta-analysis of retrospective studies that showed a strong 
relationship between second-trimester miscarriage and the inherited 
thrombophilias, as mentioned above.
Antiphospholipid syndrome
All women with RPL should be screened for antiphospholipid 
syndrome before the next pregnancy.[26] The work-up includes 
testing for ACA IgG and IgM, and lupus anticoagulant (LA); it 
Table 4. Evidence-based approach to the work-up of couples with recurrent pregnancy loss, to identify a possible underlying cause
Genetic counselling and screening
• Genetic counselling: All patients
• Amniocentesis: All women of advanced maternal age 
• Karyotyping of products of conception: All patients
• Parental karyotyping: Only patients with a personal or family history of genetic abnormalities or when the results of karyotyping of the abortus 
are abnormal
ACAs (IgG and IgM) and lupus anticoagulant
• All patients, before the next pregnancy
• On 2 separate occasions, 6 - 8 weeks apart
Imaging
• Pelvic ultrasound: All patients
• Hysteroscopy: All patients
• Depending on anomalies detected, sonohysterography, a hysterosalpingogram or laparoscopy can be considered
Screening for infection
• Syphilis testing: All patients
TSH, fasting glucose/HbA1c
• If clinical manifestations of either disease is present or if the patient is known to have the disease
ACAs = anticardiolipin antibodies; TSH = thyroid-stimulating hormone; HbA1c = glycosylated haemoglobin.
Table 5. Controversial factors in the work-up and management of recurrent pregnancy loss
Screening for inherited thrombophilia
• Association with RPL is controversial
• Depends on whether RCOG[1] or ACOG[13] guidelines are followed
• RCOG: Test all women with a history of thromboembolism planning pregnancy. Test for factor V Leiden mutation, PGM and protein S deficiency 
when indicated
• ACOG: Testing only useful if results will affect management plan, not useful in situations where treatment is indicated for other risk factors. Test for FVL 
mutation, PGM, antithrombin, protein C and protein S deficiency when indicated
Immunological testing and therapy (uterine NK cells and G-CSF)
• Currently not indicated, still in research phase
Luteal phase defect
• No standardised diagnostic method available
• If progesterone is supplemented, it should be done from ovulation until 7 - 9 weeks’ gestation
Thyroid function 
• Controversial whether patients asymptomatic for thyroid disease must be screened routinely for thyroid dysfunction
• Some authors recommend screening all patients with RPL for thyroid peroxidase antibodies, some limit it to cases where all other causes have been excluded
• Not recommended by RCOG guidelines
RCOG = Royal College of Obstetricians and Gynaecologists; ACOG = American College of Obstetricians and Gynecologists; FVL = factor V Leiden; PGM = prothrombin gene mutation; NK cells = natural 
killer cells; G-CSF = granulocyte-macrophage colony-stimulating factor.
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should be done twice, 6 - 8 weeks apart, to rule out a false-positive 
result. The diagnosis of antiphospholipid syndrome requires at least 
two positive results for either LA or ACA IgG or IgM. Women with 
one positive test result and a second negative test result should have 
a third test to confirm the diagnosis. False-positive results may be 
due to infection, suboptimal methods of sample collection and 
preparation, and lack of standardisation of laboratory testing.
Infectious causes
A recent review article concluded that most patients with a history 
of RPL do not benefit from an extensive infection work-up.[27] The 
exception is untreated syphilis.
Thyroid function 
Thyroid function should be assessed in women known to have a 
history of thyroid disease or with the clinical manifestations thereof. 
The American Thyroid Association recommends measuring serum 
thyroid-stimulating hormone in pregnant women in the following 
cases:[28]
• symptomatic for thyroid disease
• from an area known with iodine insufficiency
• family or personal history of thyroid disease
• thyroid peroxidase antibodies present
• type 1 diabetes
• history of preterm delivery or miscarriage
• history of head or neck radiation
• morbid obesity
• infertility
• older than 30 years.
Screening of asymptomatic women for subclinical thyroid disease is 
controversial. Currently screening for thyroid disease of all women 
who wish to fall pregnant is not recommended, since there are no 
data to confirm that such a screening mandate has any meaningful 
outcome. However, certain authors recommend measurement of 
thyroid peroxidase antibodies in patients with RPL or preterm birth, 
where no other cause could be identified.[29]
Evaluation of ovarian reserve
Taking blood for follicle-stimulating hormone (FSH) concentrations 
on day 3 of the menstrual cycle can be considered in the evaluation 
of RPL in women of any age group. In a retrospective comparative 
analysis, day 3 serum FSH or oestradiol levels, or both, were elevated 
in 58% of women with unexplained RPL.[30]
Luteal phase defect
There is no standardised diagnostic method available to assess 
the true incidence and effect of luteal phase defect. Endometrial 
biopsy is not recommended, since studies have shown that it does 
not predict fertility status. Serum progesterone measurement is 
unreliable, and it is not predictive of pregnancy outcome.[22]
Medical work-up
Laboratory testing may be indicated in women with clinical mani-
fest ations or a history suggestive of a medical disorder.
Treatment options
The management of RPL should be guided by the underlying cause. 
However, all couples should be treated sensitively, sympathetically, 
and with appropriate emotional support. Best practice is to refer 
couples to a specialist clinic.
Conclusion
The evidence-based recommendations for investigating couples with 
RPL in order to identify an underlying cause are summarised in 
Table 4. However, some aspects (including causes, investigations and 
management) are still surrounded by some controversy (Table 5), 
and further studies are needed in order to confirm or exclude their 
role in the approach to a couple with RPL.
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